Investors have boosted Re-Vana Therapeutics’ ambition to develop sustained-release eye disease drugs, putting up $11.9 million in series A funding on the back of nonclinical ocular safety and efficacy studies.
BELFAST, Northern Ireland, Nov. 30, 2022 /PRNewswire/ -- Re-Vana Therapeutics Ltd, a privately-held specialty drug delivery company developing sustained-release therapeutics for the treatment of vision-threatening ocular diseases, today announced the closure of its Series A round with $11.9 million in funding, an oversubscription of $4 million. The financing was led by Visionary Ventures. Additional investors include ExSight Ventures, InFocus Capital Partners and existing U.K. investors, Qubis Ltd, Co-Fund NI, and TechStart Ventures.